



Schizophrenia polygenic risk score in psychosis proneness

Patricia Mas-Bermejo^{1,2} · Sergi Papiol^{3,4,5} · Marc Via^{6,7,8} · Paula Rovira^{9,10,11,12} · Pilar Torrecilla¹³ · Thomas R. Kwapił¹⁴ · Neus Barrantes-Vidal^{5,13,15} · Araceli Rosa^{1,2,5}

Received: 9 February 2023 / Accepted: 29 May 2023 / Published online: 10 June 2023
© The Author(s) 2023

Abstract

Schizophrenia (SZ) is a complex disorder with a highly polygenic inheritance. It can be conceived as the extreme expression of a continuum of traits that are present in the general population often broadly referred to as schizotypy. However, it is still poorly understood how these traits overlap genetically with the disorder. We investigated whether polygenic risk for SZ is associated with these disorder-related phenotypes (schizotypy, psychotic-like experiences, and subclinical psychopathology) in a sample of 253 non-clinically identified participants. Polygenic risk scores (PRSs) were constructed based on the latest SZ genome-wide association study using the PRS-CS method. Their association with self-report and interview measures of SZ-related traits was tested. No association with either schizotypy or psychotic-like experiences was found. However, we identified a significant association with the Motor Change subscale of the Comprehensive Assessment of At-Risk Mental States (CAARMS) interview. Our results indicate that the genetic overlap of SZ with schizotypy and psychotic-like experiences is less robust than previously hypothesized. The relationship between high PRS for SZ and motor abnormalities could reflect neurodevelopmental processes associated with psychosis proneness and SZ.

Keywords Polygenic risk score · Genetic overlap · Schizophrenia · Schizotypy · Psychotic-like experiences · Motor abnormalities

Patricia Mas-Bermejo and Sergi Papiol contributed equally to this work.

✉ Araceli Rosa
araceli.rosa@ub.edu

- ¹ Secció de Zoologia i Antropologia Biològica. Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals. Facultat de Biologia, Universitat de Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain
- ² Institut de Biomedicina de la Universitat de Barcelona, Barcelona, Spain
- ³ Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, 80336 Munich, Germany
- ⁴ Max Planck Institute of Psychiatry, Munich, Germany
- ⁵ CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- ⁶ Brainlab, Cognitive Neuroscience Research Group, Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Barcelona, Spain
- ⁷ Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain

- ⁸ Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
- ⁹ Vicerektorat de Recerca, Investigadora Postdoctoral Margarita Salas, Universitat de Barcelona, Barcelona, Spain
- ¹⁰ Instituto de Neurociencias, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, Spain
- ¹¹ Departamento de Psiquiatría, Facultad de Medicina, Universidad de Granada, Granada, Spain
- ¹² Instituto de Investigación Biosanitaria Ibs.Granada, Granada, Spain
- ¹³ Department of Clinical and Health Psychology, Universitat Autònoma de Barcelona, Barcelona, Spain
- ¹⁴ Department of Psychology, University of Illinois at Urbana-Champaign, Champaign, IL, USA
- ¹⁵ Sant Pere Claver-Fundació Sanitària, Barcelona, Spain

Introduction

Schizophrenia (SZ) is a severe and disabling mental disorder that affects around 24 million people worldwide [1]. Family and twin studies have provided evidence of its multifactorial origin, with a strong genetic component evidenced by heritability estimates around 70–80% [2, 3]. As confirmed over the last few years by genome-wide association studies (GWAS), the genetic architecture of this disorder is highly polygenic, with the cumulative effects of a large number of genes involved. However, although numerous risk loci have already been identified, these variants still only explain a relatively small fraction of the overall heritability of SZ [4, 5].

According to the dimensional view of mental disorders, the psychosis phenotype is manifested across a dynamic continuum in which SZ represents the most extreme of a much broadly distributed clinical expression of psychosis liability expressed as schizotypy traits and psychotic-like experiences in the general population [6–9]. SZ and its subclinical presentations are heterogeneous and this heterogeneity can be captured in a multidimensional structure, with positive, negative and disorganized symptom dimensions most commonly identified. The positive dimension involves odd beliefs ranging from trait-like features such as magical thinking to sub/clinical symptoms like delusions, unusual perceptual experiences that include illusions and hallucinations, suspiciousness and paranoia. The negative or deficit dimension comprises anhedonia, flattened affect, alogia, anergia, and disinterest in the world. And the disorganization dimension involves disruptions in the organization and expression of thought, communication, emotion, and behaviour. These dimensions range from adaptation or minimal dysfunction to overt clinical psychosis, possibly reflecting certain genetic and non-genetic etiological continuity [10–12]. Subclinical traits are hypothesized to be genetically less complex than clinical phenotypes and more directly related to aetiological factors than categorical diagnostic groups, thus being considered interesting candidate phenotypes for the study of SZ [13–16].

To date, little is known about the contribution of genetic risk loci for SZ to SZ-related traits in the general population [17]. In the pre-GWAS era, schizotypy and psychotic-like experiences have been considered as phenotypes in candidate gene studies attempting to identify susceptibility variants related to SZ and both have been found to be associated with previously reported genetic risk variants for this disorder [18–23]. More recently, GWAS have laid the groundwork for the identification of the polygenicity of SZ. One of the tools that GWAS have facilitated is the calculation of Polygenic Risk Scores (PRSs), by computing the sum of an individual's risk alleles weighted by the

effect sizes of such alleles. PRSs provide an estimation of the individual genetic liability to a trait or a disorder and can be used to study the shared genetic aetiology among complex traits at the population level [24].

In the field of psychosis proneness, studies applying PRSs for SZ (SZ-PRSs) to examine the genetic overlap between SZ and its related subclinical phenotypes so far have led to controversial results. On the one hand, several previous studies failed to detect an association between SZ-PRSs and psychotic-like experiences when examining population-based samples of varying sample sizes (e.g., [25–28]). Similarly, Nenadić and colleagues [29] tested the hypothesized association of schizotypy and SZ-PRSs in two non-clinical samples and were not able to find a significant association either. In line with these negative results, a previous study exploring the same hypothesis in a sample of male army recruits reported an inverse association with schizotypy, but follow-up analyses revealed that the association only held under stressful conditions, suggesting an environmental impact rather than a SZ-related genetic influence [30]. However, there is also a growing number of studies with significant findings that support the existence of a shared genetic background between this disorder and its related phenotypes. For instance, four studies examining relatively large general population samples found evidence of an association between SZ-PRSs and multiple measures of psychotic-like experiences [31–34]. Likewise, Karcher and colleagues [35] recently reported an association between SZ-PRSs and distressing psychotic-like experiences in a population-based cohort of children. Regarding schizotypy, Docherty et al. [36] examined a sample of healthy individuals and found a male-specific association between SZ-PRSs and schizotypy. Additionally, van Os et al. [37] reported an association with both positive and negative schizotypy in a similar sample. It should be pointed out that the authors of this last study, as well as Zammit and colleagues [25], used interview-based measures to assess schizotypy and psychotic-like experiences instead of self-report questionnaires, which might have avoided certain phenotypic assessment biases.

Given this background, the aim of this study was to examine the contribution of SZ genetic risk variants to SZ-related traits by analyzing whether SZ-PRSs are associated with SZ-related phenotypes in a sample of non-clinical young adults. The phenotyping of participants was enriched by including the assessment of self-reported traits and psychotic-like experiences as well as face-to-face interviews of a broad range of subclinical experiences and symptoms.

Sample and methods

Participants

The sample of the present study was part of the ongoing Barcelona Longitudinal Investigation of Schizotypy Study (BLISS) [38–40]. At T1 of the BLISS, 547 unselected college students enrolled in Psychology courses at the *Universitat Autònoma de Barcelona* (UAB) and 261 students from seven technical training schools in Barcelona were initially screened with self-report questionnaires. At T2, a subsample of 253 individuals (i.e., 214 from the UAB and 39 from technical training schools) oversampled for schizotypy scores to ensure enough variance in the construct of interest was selected to conduct in depth examinations comprising a wide range of interview, questionnaire and experience sampling methodology measurements. This study uses data from the 253 subjects of this T2 subsample, although 25 of them were excluded during the quality control of genetic data. Out of the final 228 participants, 164 were women (71.9%) and 64 were men (28.1%); with a mean age of 19.6 years (SD 2.9, range 17–44) and 20.8 (SD 2.3, range 18–29), respectively. Seven percent of them had a family history of psychotic disorder. All subjects volunteered to take part in the study and provided written informed consent when the assessments were carried. Ethical approval was obtained from local research ethics committees.

Psychometric assessment

Psychotic-like experiences were assessed with the Spanish version of the Community Assessment of Psychic Experiences (CAPE) [41], which has shown to be valid and reliable in general population samples [42, 43]. This 42-item self-report questionnaire evaluates the lifetime prevalence of three dimensions of symptoms: the positive, negative and depressive dimensions. Frequency is rated on a 4-point Likert scale from 1 (*never*), 2 (*sometimes*), 3 (*often*), to 4 (*nearly always*). The positive and negative dimensions were used in this study.

Schizotypy was assessed with the Wisconsin Schizotypy Scales (WSS), which include the Perceptual Aberration, Magical Ideation, Revised Social Anhedonia and Physical Anhedonia scales [44–47]. Subjects from the technical training schools completed the short version of the self-report scales [48]. Confirmatory factor analyses of the four scales in samples of 6137 and 2292 young adults for the original and short version of the WSS, respectively, revealed a positive and a negative schizotypy factor, which accounted for 80% of the variance [49, 50]. Positive

schizotypy tapped magical thinking and abnormal perceptual experiences, whereas negative schizotypy captured social and physical anhedonia. In the present study, participants were assigned positive and negative schizotypy factor scores in order to use them for the analyses, thereby enabling the comparison between data obtained from the short and the original versions of the WSS.

All participants were interviewed by trained psychologists with the Comprehensive Assessment of At-Risk Mental States (CAARMS) [51]. This semi-structured interview consists of seven subscales: (i) Positive symptoms, (ii) Cognitive change, attention, concentration, (iii) Emotional disturbance, (iv) Negative symptoms, (v) Behavioural change, (vi) Motor/physical change and (vii) General psychopathology. Severity ratings were used in this study for each subscale. These variables were dichotomized; splitting individuals who scored zero (no symptoms at all) from those who scored 1 or more (i.e., presenting some degree of symptomatology).

Genotyping, quality control and imputation

DNA was extracted from saliva or cotton swabs using the prepIT-L2P kit (DNA Genotek Inc., Ottawa, Ontario, Canada) and the RealPure Genomic DNA Extraction Kit (Duzviz S.L.U., Valencia, Spain), respectively. DNA samples were genotyped at the *Centro Nacional de Genotipado* (CEGEN-PRB3-ISCI3; CNIO-Madrid) using the Illumina Infinium Global Screening Array-24 v2.0 (GSA) Bead-Chip. GenomeStudio v2.0.4 (Illumina Inc., San Diego, CA, USA) was used to generate the genotype calls. The quality control (QC) was carried out with PLINK v1.9 (www.cog-genomics.org/plink/1.9/) [52] to exclude SNPs that: had a missing call rate > 2%; had a Minor Allele Frequency (MAF) < 0.1%; or deviated from Hardy–Weinberg equilibrium with a P-value < 0.001. Subjects were excluded when: had a missing call rate > 2%; were related with other participants or duplicated samples according to the pairwise identity by descent method (PI_HAT > 0.25); or had non-European ancestry as inferred with a Multi-dimensional Scaling (MDS) analysis in which the first 10 ancestry components were extracted. From the total sample of 253 non-clinical individuals, 25 subjects were excluded due to this exhaustive QC leaving a sample of 228 subjects. MDS components were then recalculated in this final sample and the first two were used in all models as independent variables. Imputation was carried out using the Haplotype Reference Consortium panel (www.haplotype-reference-consortium.org) [53] in the Michigan Imputation Server [54]. Post-imputation QC was performed to filter out SNPs with a MAF < 1% and R_{sq} < 0.3. A total of 7,755,414 SNPs passed post-imputation QC.

Calculation of PRSs

PRSs were calculated for each of the 228 participants based on the latest SZ GWAS of the Psychiatric Genomics Consortium [4]. PRS-CS tool was used to infer posterior SNP effect sizes under continuous shrinkage priors [55]. We did a small-scale grid search setting the global shrinkage parameter ϕ at: 1.00E–01, 1.00E–02, 1.00E–03, 1.00E–04, 1.00E–05 and 1.00E–06 besides selecting the auto setting, where ϕ is automatically learnt using a fully Bayesian approach. The polygenic profiles were computed by summing the number of risk alleles that each individual carries multiplied by the inferred posterior SNP weights, including a total of 1,107,471 SNPs.

Statistical analyses

All analyses were conducted using RStudio (v1.1.456; RStudio, Inc.). An a priori power analysis was carried out with the `pwr.f2.test` function of the `pwr` R package (v1.3.0) in order to estimate the minimum effect size that we could identify with a power of 80% considering our current sample size ($N = 228$) and an alpha level of 0.05. Result showed that the minimum effect size detectable was $f^2 = 0.064$ (i.e., $R^2 = 0.061$). The association between the psychometric variables and the polygenic scores at the 7 different ϕ values was tested using linear and logistic regression models for the continuous and dichotomized variables, respectively. The analyses were performed for both the total sample and by sex, and were adjusted for age, sex, recruitment center (i.e., UAB or technical training schools students) and the first two ancestry-based MDS components (excluding sex in sex-stratified analyses). The amount of variance on the psychometric variables explained by the PRSs alone was estimated calculating the incremental Adjusted R^2 (incr. Adj. R^2) for continuous variables and the incremental Nagelkerke's pseudo- R^2 (incr. Nagelkerke's R^2) for dichotomized variables, which are the difference in Adjusted R^2 or Nagelkerke's R^2 between the full model and the baseline model

(i.e., including all variables except the PRSs). We applied the False Discovery Rate (FDR) method [56] correcting for the PRSs derived from the 7 different ϕ values to correct for multiple testing.

Results

Association between PRSs for SZ and the self-report scales

Of the 228 non-clinical subjects with genetic data, 226 had valid scores for the CAPE (i.e., assessment of psychotic-like experiences) and all 228 participants completed the WSS (i.e., schizotypy assessment). Descriptive statistics and correlations between the two measures are presented in Table 1.

Linear regression analyses performed to test the association between SZ-PRSs and the scores of the two dimensions of psychotic-like experiences showed no significant results for any of the 7 ϕ values tested (Supplementary Table S1). Likewise, no associations were found between the positive and negative schizotypy scores and the SZ-PRSs derived from the 7 ϕ values (Supplementary Table S2).

Association between SZ-PRSs and the CAARMS interview subscales

The CAARMS subscales were available for all 228 participants, with the exception of the General Psychopathology subscale, for which data was available for 218 individuals. The frequency distribution of the dichotomized seven subscales is reported in Table 2.

Logistic regressions testing the association between the SZ-PRSs and the seven subscales of the CAARMS showed a significant association of the Motor Change subscale with the PRSs derived from 5 of the 7 ϕ values tested (Table 3). This association survived FDR correction. The maximum amount of variance on this variable was explained by the PRS computed at $\phi = 1.00E-02$ (incr.

Table 1 Descriptive statistics and Spearman's correlations of the self-report scales

		Descriptive statistics		Spearman's correlations			
		Mean (SD)	Range	CAPE dimension		WSS factor	
				Positive	Negative	Positive	Negative
CAPE dimension	Positive	8.48 (5.04)	0 to 23	0.382***		0.697***	0.125
	Negative	10.31 (5.62)	0 to 35			0.377***	0.436***
WSS factor	Positive	– 0.32 (0.85)	– 1.56 to 2.24				0.115
	Negative	0.01 (1.03)	– 1.57 to 4.27				

SD standard deviation

***Correlation is significant at $P < 0.001$

Table 2 Frequency distribution of the CAARMS interview subscales

CAARMS subscale		Frequency	Valid percent
Positive symptoms	0	141	61.8
	≥ 1	87	38.2
Cognitive change	0	138	60.5
	≥ 1	90	39.5
Emotional disturbance	0	158	69.3
	≥ 1	70	30.7
Negative symptoms	0	131	57.5
	≥ 1	97	42.5
Behavioural change	0	130	57
	≥ 1	98	43
Motor change	0	142	62.3
	≥ 1	86	37.7
General psychopathology	0	66	30.3
	≥ 1	152	69.7

Nagelkerke's $R^2 = 5.2\%$), which showed an odds ratio (OR) of 2.56 indicating that in our sample it is 2.56 times more likely to present motor changes for each increase of one standard deviation of the PRS.

We did not find significant associations between the other CAARMS subscales and any of the ϕ values tested (Supplementary Table S3).

To better visualize the effect of the SZ-PRSs on the scores of the Motor Change subscale, we constructed a plot representing the variation of the ORs for the risk of scoring > 0 on this subscale with increasing SZ-PRSs (Fig. 1). The sample was split based on quartiles using the standard residuals of the SZ-PRSs derived from the auto setting and corrected for age, sex, recruitment center, and the first two ancestry-based MDS components. Significant differences were found between the lowest and highest strata of data (Q1 and Q4, respectively; OR 3.41; $P = 0.003$) pointing to an increasing risk of motor changes with increasing PRS values.

Table 3 Results of the regression models between the CAARMS Motor Change subscale and the PRSs derived from the 7 ϕ values of the PRS-CS method

ϕ value	Effect (β)	Nagelkerke's R^2 model	Incr. Nagelkerke's R^2	OR	P value	FDR P value
1.00E-01	0.657	0.102	0.050	1.92	0.003**	0.012*
1.00E-02	0.940	0.104	0.052	2.56	0.003**	0.012*
1.00E-03	1.266	0.096	0.044	3.54	0.006**	0.015*
1.00E-04	1.512	0.082	0.030	4.53	0.024*	0.034*
1.00E-05	1.493	0.069	0.016	4.45	0.095	0.111
1.00E-06	1.309	0.062	0.009	3.70	0.204	0.204
Auto	1.656	0.093	0.040	5.23	0.009**	0.016*

OR Odds Ratio

*Association is significant at $P < 0.05$; **association is significant at $P < 0.01$

Association of SZ-PRSs and the psychometric variables by sex


Sex-stratified analyses revealed a significant association of the SZ-PRSs with the CAARMS Motor Change subscale in women, for 4 of the 7 ϕ values tested. The PRS computed at $\phi = 1.00E-01$ explained the maximum amount of variance on this variable (incr. Nagelkerke's $R^2 = 5\%$; OR 1.96). However, these results did not survive FDR correction (Supplementary Table S4). No significant associations were found when performing the analyses in men (Supplementary Table S5).

Discussion

The present study aimed to investigate in a non-clinically ascertained sample whether SZ-PRSs were associated with SZ-related subclinical phenotypes, that is, schizotypy dimensions, psychotic-like experiences and interview-ratings of a broad range of subclinical experiences and symptoms.

When analyzing the two self-report assessments, we did not find any significant association of the polygenic burden for SZ with psychotic-like experiences or with schizotypy. In the past years, in accordance with an increasing support for the psychosis extended phenotype hypothesis (e.g., [9–11]), many attempts have been made in order to find evidence of an overlapping genetic architecture between SZ and its related phenotypes. However, the previous literature specifically examining psychotic-like experiences and schizotypy in relation to SZ-PRSs shows inconsistent results, so the existence of a genetic overlap with these phenotypes is still unclear. Although some studies have found evidence of a shared genetic aetiology with different measures of psychotic-like experiences and schizotypy [31–34, 36], our findings indicating a lack of an association concurs with several other studies. For instance, both Sieradzka et al. [26] and Zammit et al. [25] examined in relatively large population-based samples whether SZ-PRSs were associated with

Fig. 1 Motor change risk increase with the polygenic burden of SZ. Odds ratios (OR) for the risk of presenting CAARMS Motor Change score > 0 between high and low SZ-PRS after dividing the sample based on quartiles using the standard residuals of the SZ-PRS corrected for age, sex, recruitment center, and the first two ancestry-based MDS components



different measures of psychotic-like experiences and neither of them identified any significant association. In line with these negative results, van Os et al. [28] investigated in two independent healthy comparison samples whether SZ-PRSs were associated with psychotic-like experiences assessed with the CAPE self-report questionnaire and did not detect any significant association either. Finally, our results are consistent with those of Nenadić and colleagues [29], who were unable to identify any significant association when exploring the genetic overlap between SZ-PRSs and schizotypy in two non-clinical samples. This led them to propose that schizotypy should be regarded as a wider phenotype beyond merely harbouring risk for SZ, consistent with dimensional conceptualizations of the dual nature of schizotypy, as any other trait, as an indicator of both normal individual differences as well as behavioural risk for psychosis [57]. Therefore, specific genes giving risk for SZ may in a sense wash out in the larger pool of schizotypic individuals, which does not diminish the utility of schizotypy, but

highlights that it is an interesting construct in its own right, not simply a prodromal or risk condition for SZ. Nevertheless, the comparison of previous results between these types of studies should be done with caution as the different instruments and questionnaires used for the psychometric assessment could be capturing different underlying concepts [58].

Other plausible explanations for such a lack of associations in the literature have been pointed out. Nenadić et al. [29] suggested the possibility that, in the non-clinical part of the psychosis continuum, environmental stressors may have a larger effect on the phenotypic expression of SZ-related traits than genetic predisposition, which would be in consonance with the low variance of different subclinical phenotypes that SZ-PRSs explain. Some studies have already found evidence of an environmental contribution to the expression of psychotic-like experiences and schizotypy in samples from the general population. For example, a link between psychotic-like experiences and smoking and using cannabis in general population samples has been

described [59–61]. In a similar fashion, Pries and colleagues [62] computed a score of cumulative environmental load that included childhood adversity, winter-birth, cannabis use, and hearing impairment and found that it was associated with positive, negative, and total schizotypy. Additionally, in line with these findings a previous work identified an association between SZ genetic load and positive schizotypy in a sample of male army recruits, but only at the stressed condition of military induction, which denoted an environmental influence [30]. It is also likely that in the non-clinical end of the psychosis continuum, plasticity alleles rather than risk alleles (i.e., alleles that confer sensitivity to both positive and negative environmental influences rather than alleles that only confer vulnerability in the presence of environmental adversity) play a more relevant role in the underlying pathways that lead to the expression (or not) of these sub-clinical manifestations. Therefore, PRSs that likely reflect susceptibility to environmental influences rather than risk to develop SZ might better capture the genetic architecture of these subclinical traits [63].

Another plausible explanation for the increasing number of negative results in previous research could be that, like SZ, its related subclinical phenotypes might also be determined by different types of genetic variants beyond common SNPs considered in PRS computation. In fact, SNP-based heritability estimates for SZ indicate that common variation only explains around 24% of the variance in SZ liability [4]. Therefore, the lack of significant associations cannot entirely rule out the possibility of a genetic overlap between these phenotypes, as it could mainly be conformed of other types of genetic variation such as copy number variants or rare variants. Finally, it could be that the PRSs constructed based on variants associated with clinically diagnosed SZ might not be able to capture the subclinical manifestations of psychosis since these typically overlap within a transdiagnostic mix of symptoms [64]. Thus, future research using PRSs built with variants associated with these subclinical symptoms in non-clinical or at-risk samples could elucidate this question.

Regarding the CAARMS interview, our findings seem to identify an association between the polygenic risk for SZ and the presence of motor abnormalities. We found an association with the Motor/physical Change subscale, which evaluates subjectively experienced difficulties with movement and objective signs of catatonia, including: subjective complaints of impaired motor functioning; informant reported or observed changes in motor functioning; subjective complaints of impaired bodily sensation; and subjective complaints of impaired autonomic functioning [51]. Individuals reporting some degree of motor abnormalities on the Motor Change subscale presented higher SZ-PRSs, which suggests that non-clinical individuals with a higher end of polygenic burden for SZ already present some degree of motor

dysfunction despite being functional young adults, in comparison with those subjects with a low SZ polygenic load. In fact, when we divided our sample into quartiles of increasing PRS, a trend towards an increase in motor changes with increasing SZ polygenic load could be observed, where the risk of presenting some motor abnormalities was three times higher for individuals in the highest quartile than those in the lowest quartile. Given that SZ is known to affect men and women differently [65], the association analyses were also conducted based on gender. The association between the SZ polygenic burden and the presence of motor abnormalities found in the whole sample was also detected in the female subsample, although in this case all significance was lost after FDR correction. Regarding men, no significant association was found. However, given that the size of the male subsample was considerably small ($N=64$), we cannot rule out the possibility that this association also exists in men. Moreover, it could be observed that the association was stronger for the whole sample than for the female subset only, which suggests that men were actually contributing to the significance of the association, rather than diminishing it. Nevertheless, this should be considered cautiously, given that we did not have specific hypotheses about this domain relative to the other domains tapped by the CAARMS.

Some studies have estimated that up to 80% of patients with SZ present some motor anomalies, already observed very early during premorbid development in most of these patients [66]. These abnormalities have been associated with poorer psychopathological, cognitive, and social outcomes [67–69]. In fact, motor impairment constitutes a key transdiagnostic feature indexing disease severity [70, 71] and a risk factor for conversion to psychosis [72, 73]. Consistent with recent claims of a severity continuum of psychopathology, in which established psychosis (e.g., SZ) might index the extreme end of this continuum [74], SZ-PRSs might also be reflective of a severity score and thus, be more likely to detect most severe manifestations in a non-clinical sample of young adults. The association between SZ-PRSs and the presence of motor abnormalities might be detecting those individuals with poorer functioning and with increased liability for transitioning to clinical at-risk states. It remains to be established how these results connect with neurodevelopmental processes and if PRSs are able to finally shed a light in the interplay between genetic risk, neurodevelopmental processes, and subclinical traits in the general population.

The findings of the present study should be interpreted with caution bearing in mind some limitations. On the one hand, given the face-to-face nature of part of the psychometric assessment, our sample was relatively small for the type of investigation carried out and a slight lack of statistical power has to be acknowledged. On the other hand, the sex-stratified analyses performed may be biased since more than 70% of the participants were women and the size of the male

subsample (N = 64) will likely have affected our statistical power. Additionally, we had no knowledge of the developmental and drug use history of the participants, which could have added an interesting insight to the analyses carried out. Finally, due to the non-clinical nature of the sample analyzed in this study, most participants reported relatively low scores on the psychometric scales. On the CAARMS interview, especially, a clear floor effect could be observed as this interview was initially designed to evaluate help-seeking individuals rather than non-clinical subjects—although we highlight that the present sample was oversampled for both positive and negative schizotypy and psychotic-like experiences from a larger unselected sample. Thus, the CAARMS variables were dichotomized, which might have led to a loss of statistical power [75]. Even so, it is worth noting that we were still able to detect a robust association with the Motor Change subscale of this interview.

Conclusions

In conclusion, our results seem to suggest that schizotypy and psychotic-like experiences share less genetic variability with SZ than initially hypothesized and that SZ-PRSs are able to capture the subjective motor changes measured with the CAARMS interview presented in some healthy subjects from the general population. Further studies in larger non-clinical samples are required in order to finally unravel the shared genetic background between this disorder and its subclinical phenotypes and to ensure the replicability of the association with motor abnormalities found in the present study. Moreover, the replication of this finding across levels of severity expression (e.g., at risk mental states and first episode psychosis) would allow us to both understand more in depth the nature of this association and test whether, as it would be expected, this association becomes more evident at greater severity expressions of the extended psychosis phenotype that presumably index increasing genetic load for SZ.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00406-023-01633-7>.

Author contributions TRK, NB-V and AR contributed to the conceptualization of the study and NB-V and AR designed the methodology, conducted the investigation, provided resources and acquired financial support. Genetic procedures were performed by PM-B, SP and MV. PM-B and SP carried out the statistical analyses. Sample collection and psychometric assessment was supervised by NB-V and SP and AR supervised the execution of the research activity. SP, PR, PT and NB-V were consulted about the results and/or genetic procedures. The original draft of the manuscript was written by PM-B and AR and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The present work was supported by

the Spanish Ministry of Economy and Competitiveness (PSI2017-87512-C2-01 and 02-R; PID2020-119211RB-I00) and Generalitat de Catalunya (*Suport als Grups de Recerca* 2021SGR00706 and 2021SGR01010). P. Mas-Bermejo was funded by *Institut de Biomedicina de la Universitat de Barcelona* (IBUB) and the PhD scholarship program FI-SDUR (2021-FISDU-00032) from *Agència de Gestió de Ayudas Universitaries y de Investigació* (AGAUR). The genotyping service was carried out at CEGEN-PRB3-ISCI; it is supported by grant PT17/0019, of the PE I + D + i 2013–2016, funded by ISCI and ERDF.

Data availability The data that support the findings of this study are available from the authors AR and NB-V upon reasonable request.

Declarations

Conflict of interest The authors have no competing interests to declare that are relevant to the content of this article.

Ethical approval This study was approved by Ethics Committee of the *Universitat Autònoma de Barcelona* (*Comissió d'Ètica en l'Experimentació Animal i Humana* [CEEAH]; <https://www.uab.cat/web/investigacio-humana/presentacio-1345713929159.html>) and was therefore performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Consent to participate All subjects volunteered to take part in the study and gave written informed consent for their participation.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396:1204–1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)
2. Legge SE, Santoro ML, Periyasamy S et al (2021) Genetic architecture of schizophrenia: a review of major advancements. *Psychol Med* 51:2168–2177. <https://doi.org/10.1017/S0033291720005334>
3. Cardno AG, Gottesman II (2000) Twin studies of schizophrenia: from bow-and-arrow concordances to Star Wars Mx and functional genomics. *Am J Med Genet* 97:12–17. [https://doi.org/10.1002/\(SICI\)1096-8628\(200021\)97:1%3c12::AID-AJMG3%3e3.0.CO;2-U](https://doi.org/10.1002/(SICI)1096-8628(200021)97:1%3c12::AID-AJMG3%3e3.0.CO;2-U)
4. Trubetskoy V, Pardiñas AF, Qi T et al (2022) Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* 604:502–508. <https://doi.org/10.1038/S41586-022-04434-5>

5. International Schizophrenia Consortium, Purcell SM, Wray NR et al (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460:748–752. <https://doi.org/10.1038/nature08185>
6. Guloksuz S, van Os J (2021) En attendant Godot: waiting for the funeral of “schizophrenia” and the baby shower of the psychosis spectrum. *Front Psychiatry* 12:618842. <https://doi.org/10.3389/FPSYT.2021.618842>
7. Guloksuz S, van Os J (2018) The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. *Psychol Med* 48:229–244. <https://doi.org/10.1017/S0033291717001775>
8. Kwapil TR, Barrantes-Vidal N (2015) Schizotypy: looking back and moving forward. *Schizophr Bull* 41:366–373. <https://doi.org/10.1093/schbul/sbu186>
9. Barrantes-Vidal N, Grant P, Kwapil TR (2015) The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders. *Schizophr Bull* 41:S408–S416. <https://doi.org/10.1093/schbul/sbu191>
10. Kaymaz N, van Os J (2010) Extended psychosis phenotype—yes: single continuum—unlikely. *Psychol Med* 40:1963–1966. <https://doi.org/10.1017/S0033291710000358>
11. van Os J, Reininghaus U (2016) Psychosis as a transdiagnostic and extended phenotype in the general population. *World Psychiatry* 15:118–124. <https://doi.org/10.1002/wps.20310>
12. Ettinger U, Meyhöfer I, Steffens M et al (2014) Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia. *Front Psychiatry* 5:1–16. <https://doi.org/10.3389/fpsy.2014.00018>
13. Grant P (2015) Is Schizotypy per se a suitable endophenotype of schizophrenia? Do not forget to distinguish positive from negative facets. *Front Psychiatry* 6:1–4. <https://doi.org/10.3389/fpsy.2015.00143>
14. Kelleher I, Cannon M (2011) Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis. *Psychol Med* 41:1–6. <https://doi.org/10.1017/S0033291710001005>
15. Grant P, Kuepper Y, Mueller EA et al (2013) Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE)—a suitable endophenotype of schizophrenia. *Front Hum Neurosci* 7:1–11. <https://doi.org/10.3389/fnhum.2013.00001>
16. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. *Am J Psychiatry* 160:636–645. <https://doi.org/10.1176/appi.ajp.160.4.636>
17. Mistry S, Harrison JR, Smith DJ et al (2018) The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: systematic review. *Schizophr Res* 197:2–8. <https://doi.org/10.1016/j.schres.2017.10.037>
18. Schürhoff F, Szöke A, Chevalier F et al (2007) Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. *Am J Med Genet Part B Neuropsychiatr Genet* 144B:64–68. <https://doi.org/10.1002/AJMG.B.30395>
19. Meller T, Schmitt S, Stein F et al (2019) Associations of schizophrenia risk genes ZNF804A and CACNA1C with schizotypy and modulation of attention in healthy subjects. *Schizophr Res* 208:67–75. <https://doi.org/10.1016/J.SCHRES.2019.04.018>
20. de Castro-Catala M, Barrantes-Vidal N, Sheinbaum T et al (2015) COMT-by-sex interaction effect on psychosis proneness. *Biomed Res Int* 2015:1–7. <https://doi.org/10.1155/2015/829237>
21. de Castro-Catala M, Mora-Solano A, Kwapil TR et al (2017) The genome-wide associated candidate gene ZNF804A and psychosis-proneness: evidence of sex-modulated association. *PLoS ONE* 12:e0185072. <https://doi.org/10.1371/journal.pone.0185072>
22. de Castro-Catala M, Cristóbal-Narváez P, Kwapil TR et al (2017) Association between RGS4 variants and psychotic-like experiences in nonclinical individuals. *Eur Arch Psychiatry Clin Neurosci* 267:19–24. <https://doi.org/10.1007/s00406-016-0676-7>
23. Stefanis NC, Hatzimanolis A, Avramopoulos D et al (2013) Variation in psychosis gene ZNF804A is associated with a refined schizotypy phenotype but not neurocognitive performance in a large young male population. *Schizophr Bull* 39:1252–1260. <https://doi.org/10.1093/schbul/sbs110>
24. Lewis CM, Vassos E (2020) Polygenic risk scores: from research tools to clinical instruments. *Genome Med* 12:1–11. <https://doi.org/10.1186/s13073-020-00742-5>
25. Zammit S, Hamshere M, Dwyer S et al (2014) A population-based study of genetic variation and psychotic experiences in adolescents. *Schizophr Bull* 40:1254–1262. <https://doi.org/10.1093/schbul/sbt146>
26. Sieradzka D, Power RA, Freeman D, et al (2014) Are genetic risk factors for psychosis also associated with dimension-specific psychotic experiences in adolescence? *PLoS One* 9:e94398. <https://doi.org/10.1371/journal.pone.0094398>
27. Jones HJ, Stergiakouli E, Tansey KE et al (2016) Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. *JAMA Psychiat* 73:221–228. <https://doi.org/10.1001/jamapsychiatry.2015.3058>
28. van Os J, Pries LK, Delespaul P et al (2020) Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. *Psychol Med* 50:1884–1897. <https://doi.org/10.1017/S003329171900196X>
29. Nenadić I, Meller T, Schmitt S et al (2022) Polygenic risk for schizophrenia and schizotypal traits in non-clinical subjects. *Psychol Med* 52:1069–1079. <https://doi.org/10.1017/s0033291720002822>
30. Hatzimanolis A, Avramopoulos D, Arking DE et al (2018) Stress-dependent association between polygenic risk for schizophrenia and schizotypal traits in young army recruits. *Schizophr Bull* 44:338–347. <https://doi.org/10.1093/schbul/sbx074>
31. Velthorst E, Froudist-Walsh S, Stahl E et al (2018) Genetic risk for schizophrenia and autism, social impairment and developmental pathways to psychosis. *Transl Psychiatry* 8:1–11. <https://doi.org/10.1038/s41398-018-0229-0>
32. Legge SE, Jones HJ, Kendall KM et al (2019) Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. *JAMA Psychiat* 76:1256–1265. <https://doi.org/10.1001/jamapsychiatry.2019.2508>
33. Pain O, Dudbridge F, Cardno A et al (2018) Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders. *Am J Med Genet Part B Neuropsychiatr Genet* 177:416–425. <https://doi.org/10.1002/AJMG.B.32630>
34. Jones HJ, Heron J, Hammerton G et al (2018) Investigating the genetic architecture of general and specific psychopathology in adolescence. *Transl Psychiatry* 8:1–11. <https://doi.org/10.1038/s41398-018-0204-9>
35. Karcher NR, Paul SE, Johnson EC et al (2022) Psychotic-like experiences and polygenic liability in the adolescent brain cognitive development study. *Biol Psychiatry Cogn Neurosci Neuroimaging* 7:45–55. <https://doi.org/10.1016/J.BPSC.2021.06.012>
36. Docherty A, Shabalin A, Adkins D et al (2020) Molecular genetic risk for psychosis is associated with psychosis risk symptoms in a population-based UK cohort: findings from generation Scotland. *Schizophr Bull* 46:1045–1052. <https://doi.org/10.1093/SCHBUL/SBAA042>
37. van Os J, van der Steen Y, Islam M et al (2017) Evidence that polygenic risk for psychotic disorder is expressed in the domain of

- neurodevelopment, emotion regulation and attribution of salience. *Psychol Med* 47:2421–2437. <https://doi.org/10.1017/S0033291717000915>
38. Racioppi A, Sheinbaum T, Gross GM et al (2018) Prediction of prodromal symptoms and schizophrenia-spectrum personality disorder traits by positive and negative schizotypy: a 3-year prospective study. *PLoS ONE* 13:e0207150. <https://doi.org/10.1371/JOURNAL.PONE.0207150>
 39. Barrantes-Vidal N, Chun CA, Myin-Germeys I, Kwapil TR (2013) Psychometric schizotypy predicts psychotic-like, paranoid, and negative symptoms in daily life. *J Abnorm Psychol* 122:1077–1087. <https://doi.org/10.1037/A0034793>
 40. Barrantes-Vidal N, Gross GM, Sheinbaum T et al (2013) Positive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms. *Schizophr Res* 145:50–55. <https://doi.org/10.1016/J.SCHRES.2013.01.007>
 41. Stefanis NC, Hanssen M, Smirnis NK et al (2002) Evidence that three dimensions of psychosis have a distribution in the general population. *Psychol Med* 32:347–358. <https://doi.org/10.1017/S0033291701005141>
 42. Konings M, Bak M, Hanssen M et al (2006) Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. *Acta Psychiatr Scand* 114:55–61. <https://doi.org/10.1111/j.1600-0447.2005.00741.x>
 43. Mark W, Touloupoulou T (2016) Psychometric properties of “community assessment of psychic experiences”: review and meta-analyses. *Schizophr Bull* 42:34–44. <https://doi.org/10.1093/schbul/sbv088>
 44. Eckblad M, Chapman L, Chapman J, Mishlove M (1982) The revised social anhedonia scale. Unpubl test
 45. Eckblad M, Chapman LJ (1983) Magical ideation as an indicator of schizotypy. *J Consult Clin Psychol* 51:215–225. <https://doi.org/10.1037/0022-006X.51.2.215>
 46. Chapman LJ, Chapman JP, Raulin ML (1978) Body-image aberration in schizophrenia. *J Abnorm Psychol* 87:399–407. <https://doi.org/10.1037/0021-843X.87.4.399>
 47. Chapman LJ, Chapman JP, Raulin ML (1976) Scales for physical and social anhedonia. *J Abnorm Psychol* 85:374–382. <https://doi.org/10.1037/0021-843X.85.4.374>
 48. Winterstein BP, Silvia PJ, Kwapil TR et al (2011) Brief assessment of schizotypy: developing short forms of the Wisconsin Schizotypy Scales. *Pers Individ Dif* 51:920–924. <https://doi.org/10.1016/j.paid.2011.07.027>
 49. Kwapil TR, Barrantes-Vidal N, Silvia PJ (2008) The dimensional structure of the wisconsin schizotypy scales: factor identification and construct validity. *Schizophr Bull* 34:444–457. <https://doi.org/10.1093/schbul/sbm098>
 50. Gross GM, Silvia PJ, Barrantes-Vidal N, Kwapil TR (2015) The dimensional structure of short forms of the Wisconsin Schizotypy Scales. *Schizophr Res* 166:80–85. <https://doi.org/10.1016/j.schres.2015.05.016>
 51. Yung AR, Yuen HP, McGorry PD et al (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry* 39:964–971. <https://doi.org/10.1111/j.1440-1614.2005.01714.x>
 52. Chang CC, Chow CC, Tellier LCAM et al (2015) Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4:7. <https://doi.org/10.1186/S13742-015-0047-8>
 53. McCarthy S, Das S, Kretzschmar W et al (2016) A reference panel of 64,976 haplotypes for genotype imputation Europe PMC Funders Group. *Nat Genet* 48:1279–1283. <https://doi.org/10.1038/ng.3643>
 54. Das S, Forer L, Schönherr S et al (2016) Next-generation genotype imputation service and methods. *Nat Genet* 48:1284–1287. <https://doi.org/10.1038/ng.3656>
 55. Ge T, Chen CY, Ni Y et al (2019) Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* 10:1–10. <https://doi.org/10.1038/s41467-019-09718-5>
 56. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B* 57:289–300. <https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>
 57. Claridge G (1997) *Schizotypy: implications for illness and health*. Oxford University Press, Oxford
 58. Gross GM, Mellin J, Silvia PJ et al (2014) Comparing the factor structure of the Wisconsin Schizotypy Scales and the Schizotypal Personality Questionnaire. *Personal Disord* 5:397–405. <https://doi.org/10.1037/PER0000090>
 59. García-González J, Ramírez J, Howard DM et al (2020) The effects of polygenic risk for psychiatric disorders and smoking behaviour on psychotic experiences in UK Biobank. *Transl Psychiatry* 10:330. <https://doi.org/10.1038/S41398-020-01009-8>
 60. Wainberg M, Jacobs GR, di Forti M, Tripathy SJ (2021) Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. *Transl Psychiatry* 11:211. <https://doi.org/10.1038/S41398-021-01330-W>
 61. Karcher NR, Barch DM, Demers CH et al (2019) Genetic predisposition vs individual-specific processes in the association between psychotic-like experiences and cannabis use. *JAMA Psychiat* 76:87–94. <https://doi.org/10.1001/JAMAPSYCHIATRY.2018.2546>
 62. Pries LK, Dal Ferro GA, van Os J et al (2020) Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. *Epidemiol Psychiatr Sci* 29:e182. <https://doi.org/10.1017/S2045796020000943>
 63. Zhang X, Belsky J (2022) Three phases of Gene × Environment interaction research: theoretical assumptions underlying gene selection. *Dev Psychopathol* 34:295–306. <https://doi.org/10.1017/S0954579420000966>
 64. McGorry P, van Os J (2013) Redeeming diagnosis in psychiatry: timing versus specificity. *Lancet* 381:343–345. [https://doi.org/10.1016/S0140-6736\(12\)61268-9](https://doi.org/10.1016/S0140-6736(12)61268-9)
 65. Merikangas AK, Almasy L (2020) Using the tools of genetic epidemiology to understand sex differences in neuropsychiatric disorders. *Genes Brain Behav* 19:e12660. <https://doi.org/10.1111/GBB.12660>
 66. Martin L, Stein K, Kubera K et al (2022) Movement markers of schizophrenia: a detailed analysis of patients’ gait patterns. *Eur Arch Psychiatry Clin Neurosci* 272:1347–1364. <https://doi.org/10.1007/S00406-022-01402-Y>
 67. Jahn T, Hubmann W, Karr M et al (2006) Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses. *Psychiatry Res* 142:191–199. <https://doi.org/10.1016/J.PSYCHRES.2002.12.003>
 68. Cuesta MJ, Moreno-Izco L, Ribeiro M et al (2018) Motor abnormalities and cognitive impairment in first-episode psychosis patients, their unaffected siblings and healthy controls. *Schizophr Res* 200:50–55. <https://doi.org/10.1016/J.SCHRES.2017.10.035>
 69. Cuesta MJ, García de Jalón E, Campos MS et al (2018) Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning. *Schizophr Res* 200:97–103. <https://doi.org/10.1016/J.SCHRES.2017.08.050>
 70. Peralta V, Cuesta MJ (2017) Motor abnormalities: from neurodevelopmental to neurodegenerative through “functional” (neuro) psychiatric disorders. *Schizophr Bull* 43:956–971. <https://doi.org/10.1093/SCHBUL/SBX089>
 71. Poletti M, Gebhardt E, Kvande MN et al (2019) Motor impairment and developmental psychotic risk: connecting the dots and narrowing the pathophysiological gap. *Schizophr Bull* 45:503–508. <https://doi.org/10.1093/SCHBUL/SBY100>
 72. Masucci MD, Lister A, Corcoran CM et al (2018) Motor dysfunction as a risk factor for conversion to psychosis independent of medication use in a psychosis-risk cohort. *J Nerv Ment Dis* 206:356–361. <https://doi.org/10.1097/NMD.0000000000000806>
 73. Chan RCK, Cui H, Chu M et al (2018) Neurological soft signs precede the onset of schizophrenia: a study of individuals with

- schizotypy, ultra-high-risk individuals, and first-onset schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 268:49–56. <https://doi.org/10.1007/S00406-017-0828-4>
74. van Os J, Pries LK, Ten Have M et al (2022) Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. *Psychol Med* 52:1910–1922. <https://doi.org/10.1017/S0033291720003748>
75. Fedorov V, Mannino F, Zhang R (2009) Consequences of dichotomization. *Pharm Stat* 8:50–61. <https://doi.org/10.1002/PST.331>